Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab SC in OCS-dependent asthma
NCT02501629Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of reslizumab in asthma, sponsored by Teva Pharmaceutical Industries Ltd.. Started Sep 2015; status: completed.
02
Drugs
reslizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02501629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501629.